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Abstract: Pulmonary arterial hypertension (PAH) may occur as an idiopathic process or as 
a component of a variety of diseases, including connective tissue diseases, congenital heart 
disease, and exposure to appetite suppressants or infectious agents such as HIV. Untreated, it 
is a potentially devastating disease; however, diagnosis can be difficult due to the non-specific 
nature of symptoms during the early stages, and the fact that patients often present to a range 
of different medical specialties. The past decade has seen remarkable improvements in our 
understanding of the pathology associated with the condition and the development of PAH-
specific therapies with the ability to alter the natural history of the disease. This article reviews 
the evidence for screening and diagnosis of susceptible patient groups and discusses treatment 
selection and recommendations based on data available from randomized controlled trials. In 
addition, due to the complexity of the diagnostic evaluation required and the treatment options 
available, this review mandates for a multidisciplinary approach to the management of PAH. 
We discuss the roles and organizational structure of a specialized PAH center in Perth, Western 
Australia to highlight these issues.
Keywords: pulmonary hypertension, multidisciplinary care, systemic sclerosis, diagnostic 
protocol
Introduction
Pulmonary arterial hypertension (PAH) is a group of diseases which form a subset 
of those with pulmonary hypertension (PHT). PAH occurs as an idiopathic process 
(iPAH) or as a component of a variety of disease processes, including connective tissue 
diseases (CTD), congenital heart disease, and exposure to exogenous factors including 
appetite suppressants or infectious agents such as human immunodeficiency virus 
(HIV). All of these conditions share a common pattern of vascular remodeling of the 
small pulmonary arteries. An increase in pulmonary vascular resistance (PVR) results 
in progressive dyspnea, profound functional limitation, and if untreated, progression 
to right ventricular failure and death.1
PAH is often perceived as a disease with a uniformly poor outcome. However, 
the past decade has witnessed significant advances in PAH-specific therapies with 
the ability to change the course of the disease. For example, untreated PAH has an 
estimated median survival of 2.8 years, with 1-year, 3-year, and 5-year survival rates 
of 68%, 48% and 34%, respectively.2 In contrast, a prospective study of observed 
survival in 139 patients with iPAH treated with bosentan and 346 similar patients 
treated with epoprostenol, reported survival estimates after 1 and 2 years of 97% 
and 91%, respectively, in the bosentan cohort and 91% and 84% in the epoprostenol Journal of Multidisciplinary Healthcare 2009:2 68
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cohort.3 In patients with CTD-related PAH, earlier treatment 
is associated with better outcomes – the risk of death increas-
ing by 11% for every 10 mmHg increase in mean pulmonary 
arterial pressure (mPAP).4 Unfortunately, given the range of 
comorbidities associated with the disease, and the fact that 
various specialities can be confronted with PAH, translating 
the importance of early diagnosis and treatment into clinical 
practice represents an ongoing challenge.
In the initial stages, the most common symptoms of PAH 
include breathlessness, fatigue and near syncope.5 Since 
these symptoms are non-specific, PAH is often overlooked 
or under-recognized until its later, more advanced stages 
(such as the onset of right heart failure). This pattern of 
presentation may also be responsible for underestimating 
the true prevalence of the disease and explain, in part, why 
PAH is sometimes managed by cardiologists and sometimes 
by respiratory physicians. The aim of this article is twofold. 
Firstly, to provide an overview of PAH and appropriate 
diagnostic and treatment approaches, and secondly, to discuss 
the rationale and importance of a multidisciplinary approach 
to the management of this disease. The process of integrated 
PAH care provided by the Royal Perth Hospital, Western 
Australia is used as the basis for this discussion.
Classification and pathophysiology 
of PAH
Classification
PHT is defined by a mPAP 25 mmHg at rest or 30 mmHg 
with exercise. In 2003, the World Health Organization (WHO) 
revised the classification of PHT into five categories based 
in part on etiology: PAH, pulmonary venous hypertension, 
PHT associated with lung diseases and/or hypoxemia, PHT 
resulting from chronic thrombotic or embolic disease, and 
miscellaneous (Table 1).6 The classification system aims to 
frame whether PHT is a manifestation of an underlying disease 
and provides an understanding of the contexts in which PHT 
occurs. PAH is a sub-category of PHT (the two terms are 
not synonymous) and is defined as a mPAP  25 mmHg at 
rest or 30 mmHg during exercise with a normal pulmonary 
artery wedge pressure (PAWP) which excludes pulmonary 
venous hypertension.7–9 Patients with PAH can also be 
classified according to their ability to function and symptom 
Table 1 Revised clinical classification of pulmonary hypertension (Venice 2003)6
1.  Pulmonary arterial hypertension (PAH)
  1.1.  Idiopathic (IPAH)
  1.2.  Familial (FPAH)
  1.3. Associated with (APAH):
      1.3.1.  Collagen vascular disease
      1.3.2.  Congenital systemic-to-pulmonary shunts
      1.3.3.  Portal hypertension
      1.3.4.  Hiv infection
      1.3.5.  Drugs and toxins
      1.3.6.    Other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, 
myeloproliferative disorders, splenectomy)
  1.4. Associated with significant venous or capillary involvement
      1.4.1.  Pulmonary veno-occlusive disease (PVOD)
      1.4.2.  Pulmonary capillary hemangiomatosis (PCH)
  1.5. Persistent pulmonary hypertension of the newborn
2.  Pulmonary hypertension with left heart disease
  2.1.  Left-sided atrial or ventricular heart disease
  2.2.  Left-sided valvular heart disease
3.  Pulmonary hypertension associated with lung diseases and/or hypoxemia
  3.1.  Chronic obstructive pulmonary disease
  3.2.  interstitial lung disease
  3.3.  Sleep-disordered breathing
  3.4. Alveolar hypoventilation disorders
  3.5.  Chronic exposure to high altitude
  3.6.  Developmental abnormalities
4.  Pulmonary hypertension due to chronic thrombotic and/or embolic disease
  4.1. Thromboembolic obstruction of proximal pulmonary arteries
  4.2. Thromboembolic obstruction of distal pulmonary arteries
  4.3.  Non-thrombotic pulmonary embolism (tumor, parasites, foreign material)
5.  Miscellaneous: Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)Journal of Multidisciplinary Healthcare 2009:2 69
Management of PAH Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
severity. The WHO classification of functional capacity, 
an adaptation of the New York Heart Association (NYHA) 
system, has been useful in this regard (Table 2).10
Regardless of the cause, the common end result of processes 
leading to PAH is elevation of PVR, with resultant elevation 
of PAP and progression to right-sided heart failure.
Pathophysiology
Under normal conditions, the pulmonary circuit is a low 
pressures system (mPAP 12–16 mmHg). Healthy individuals 
can accommodate up to a 4-fold rise from the resting cardiac 
output with little increase in PAP, due to distensibility of the 
thin-walled pulmonary vasculature and to recruitment of 
vessels that are normally closed when at rest.11 The excess 
capacity is such that approximately 70% of the vascular bed 
must be lost before there is an increase in resting PAP.11
Most forms of PAH share a common pathophysiology 
which includes pulmonary vasoconstriction, vascular 
wall hypertrophy and thrombosis in situ.12–14 The primary 
mechanism is believed to involve endothelial dysfunction, 
resulting in over expression of endothelin (ET)-1, a 
21-amino acid peptide which, at normal levels contributes 
to the maintenance of vascular tone, mediates cardiac, renal 
and endocrine function, and plays a role in mitogenesis.15 
Endothelial dysfunction also reduces the synthesis of nitric 
oxide and prostacyclin (PgI2), impairing vasodilatory responses 
and exacerbating the dysfunctional vasoresponses caused 
by elevated ET levels.14,16 Other important pathways in the 
process of pulmonary vascular remodeling include changes in 
potassium channel expression, activation of vascular elastases, 
and increased expression of inflammatory chemokines.17 
Various growth factors, including platelet-derived growth 
factor (PDGF), fibroblast growth factor (FGF), insulin growth 
factor-1 (IGF-1), and epidermal growth factor (EGF) have also 
been postulated to be involved.18
A mutation of the bone morphogenetic protein receptor 
type II (BMPR2) gene has been identified in approximately 
50% patients with familial and iPAH.19 However, the 
relationship of this gene mutation to the broad range of associ-
ated causes of PAH remains unknown, and not all individuals 
carrying the BMPR2 mutation develop PAH. A subject who 
possesses the mutation has a 10% to 20% lifetime risk of 
acquiring PAH, while an individual without the mutation has a 
lifetime risk of PAH no different to the general population.19
Despite the multitude of perturbations that have been 
demonstrated in clinical PAH as well as in animal models 
of pulmonary hypertension, it remains unclear which are 
“causes” versus consequences of this disorder. However, 
the end result includes increased vasoconstriction, smooth 
muscle cell proliferation, decreased vasodilation, and fibrotic 
changes in medium- to small-sized pulmonary arteries.12–14
Both vasoconstrictive and hypertrophic changes lead to 
increased PVR, increasing the workload of the right ventricle. 
Initially, the right ventricle compensates to maintain adequate 
pulmonary flow, but as the increased workload causes the 
right ventricle to dilate, efficiency eventually falls. Symptoms 
such as dyspnea and fatigue appear, initially on exertion. 
Eventually and often suddenly, the right ventricle decom-
pensates and right heart failure ensues.20 Death occurs as a 
result of end-stage right heart failure or arrhythmia.21
As a result of the interconnection between pulmonary and 
cardiac pathologies, the diagnosis of PAH remains clinically 
challenging, with an umbrella of potential presentations. 
Furthermore, various specialities can be confronted with 
patients with PAH (eg, cardiologists, respiratory physicians 
and rheumatologists). It is this diverse and often non-specific 
presentation of patients that provides justification for a 
multidisciplinary approach to the detection and management 
of PAH.
Epidemiology
The incidence of idiopathic and familial PAH in the general 
population is almost certainly higher than the historical 
estimate of 1 to 2 per million population.10 More recent 
estimates vary from 5 to 52 cases per million population.22,23 
iPAH may manifest in both genders and all ages. During 
Table 2 Modified New York Heart Association classification of functional status in patients with pulmonary hypertension (PHT)
Class i Patients with PHT but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or 
fatigue, chest pain, or near syncope.
Class ii Patients with PHT resulting in slight limitation of physical activity.   They are comfortable at rest. Ordinary physical activity causes undue 
dyspnea or fatigue, chest pain, or near syncope.
Class iii Patients with PHT resulting in marked limitation of physical activity.   They are comfortable at rest. Less-than-ordinary physical activity 
causes undue dyspnea or fatigue, chest pain, or near syncope.
Class iv Patients with PHT with inability to carry out any physical activity without symptoms.   These patients manifest signs of right heart failure. 
Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.Journal of Multidisciplinary Healthcare 2009:2 70
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childhood, the condition affects both genders equally.24 
After puberty however, detection is more frequent in females 
(approximately 2:1 ratio).25,26
For other causes, PAH is associated with scleroderma in 
4.9% to 38.6% of patients,27–31 a condition which itself has a 
point prevalence of between 30.8 and 286 cases per million 
population.21 Taken together, these estimates indicate that the 
prevalence of PAH in the community may be much higher 
than previously proposed. Recently, a retrospective database 
review of all patients undergoing Doppler echocardiographic 
measures in a major regional cardiology center identified 
a significant number of patients with PAH, subsequently 
confirmed by right-heart catheterization (RHC). The estimated 
minimum prevalence of PAH in this community was 75.2 
cases per million population (47.9 case per million for iPAH 
and 27.4 cases per million for scleroderma-related PAH).32
Diagnosis and screening
Clinical presentation
Despite the gravity of the disease, detection of PAH remains 
elusive until the later stages of the disease, owing to the 
often subtle and non-specific nature of symptoms (Table 3). 
Symptoms are often difficult to dissociate from those caused 
by a known underlying pulmonary or cardiac disorder and 
frequently, there is a delay of up to 3 years between first symp-
toms and diagnosis33 – an interval that has remained stable over 
the last 20 years. The most common symptoms – exertional 
dyspnea and fatigue – reflect an inability to increase cardiac 
output during activity. Typical angina may also occur despite 
normal coronary arteries. The mechanism is unclear, but 
anginal chest pain may be due to pulmonary artery stretching 
or right ventricular ischemia.34 Over time, increasing fatigue, 
palpitations, chest pain, and increasing exercise intolerance 
develop, while hypoxemia, syncope and right-sided heart 
failure are markers of end-stage disease.
Since PHT may be associated with a variety of comorbid 
conditions, past medical history and symptomatic evidence of 
a related illness should also be considered. Potential exposure 
to toxic agents should be explored. This includes previous use 
of appetite suppressants and chemotherapy agents (including 
mitomycin-C, carmustine, etoposide, cyclophosphamide and 
bleomycin). Known exposure to HIV infection should also be 
considered together with a history of pulmonary embolism or 
deep vein thrombosis.19 Orthopnea and paroxysmal nocturnal 
dyspnea suggest elevated pulmonary venous pressure and 
pulmonary congestion due to left-sided cardiac disease. 
Raynaud phenomenon, arthralgias, or swollen hands and 
other symptoms of CTD in the setting of dyspnoea should 
raise the possibility of PAH related to CTD. A history of 
snoring or apnea provided by the patient’s partner warrants 
evaluation for sleep-disordered breathing as a potential 
causative or contributory factor.19
Diagnosis
The diagnosis of PAH is, in part, through the exclusion of 
other diseases that cause PHT. Formal guidelines have been 
published by the European Society of Cardiology (ESC)7 
and the American College of Chest Physicians (ACCP),8,19,35 
while systemic sclerosis groups have published proposed 
assessment pathways for the detection of PAH in this cohort.20 
Assessment follows a logical sequence of determining 
whether there is a risk of PAH being present, whether PAH is 
likely to be present based on initial, non-invasive evaluation, 
clarifying the underlying etiology of PAH, and delineating the 
specific hemodynamic profile, including the acute response 
to vasodilator testing.19
Physical examination
Clinical suspicion should arise in any patient presenting 
with breathlessness without overt signs of specific heart or 
pulmonary disease, particularly in diseases which may be asso-
ciated with PAH.33 On physical examination, the likelihood of 
PAH increases when certain findings are present. For example, 
a left parasternal lift produced by the impulse of the hypertro-
phied right ventricle, an accentuated pulmonary component of 
the second heart sound (S2), pansystolic murmur of tricuspid 
regurgitation, diastolic murmur of pulmonary insufficiency, 
right ventricular S3, jugular vein distention, hepatomegaly, 
peripheral edema, ascites and cool extremities.19,35 However, 
the absence of these findings does not exclude PAH.
electrocardiogram
The electrocardiogram (ECG) lacks sufficient sensitivity to 
serve as an effective screening tool for PAH. However, it 
does provide important prognostic information on anatomical 
Table 3 Symptoms and signs of pulmonary hypertension34
Symptoms Signs
Dyspnea on exertion Jugular vein distention
Fatigue Prominent right ventricular impulse
Syncope Accentuated pulmonic valve component (P2)
Anginal chest pain Right-sided third heart sound (S3)
Hemoptysis Tricuspid insufficiency murmur
raynaud’s phenomenon Hepatomegaly
Peripheral edemaJournal of Multidisciplinary Healthcare 2009:2 71
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and arrhythmic problems. ECG changes associated with PAH 
include right ventricular hypertrophy and right axis deviation 
in 87% and 79% of patients, respectively.19,35
Chest X-ray
In the majority of patients with mild PAH, a chest X-ray 
(CXR) is normal. In more advanced disease, signs sugges-
tive of PAH include enlarged main and hilar pulmonary 
arterial shadows with concomitant attenuation of peripheral 
pulmonary vascular markings (‘pruning’). Right ventricular 
enlargement is often detected by impingement of the 
anteriorly situated right ventricle silhouette into the retroster-
nal clear space on the lateral CXR.19,35
Pulmonary function tests
In the diagnosis of PAH, pulmonary function tests (PFTs) are 
used to exclude significant lung disease. Although lung func-
tion abnormalities have been described in association with 
PAH they are generally mild and unlikely to be the primary 
cause of symptoms. The exception is a marked impairment in 
the diffusion capacity for carbon monoxide (DLCO) associated 
with systemic sclerosis. The DLCO of 20% of patients with 
limited systemic sclerosis is below normal; however, a DLCO 
of  55% of predicted increases the likelihood of the presence 
or future development of PAH.19,35
Ventilation-perfusion (V/Q) lung scanning
V/Q lung scans are an important component of assessment 
and should be performed to rule out chronic thrombolic 
pulmonary hypertension (CTEPH), a potentially curable cause 
of PHT.19,35 Patients with PHT who have normal V/Q scans 
are unlikely to have chronic pulmonary embolism and more 
likely to have iPAH. In three studies, V/Q scanning showed 
sensitivity of 90% to 100% with a specificity of 94% to 100% 
for distinguishing between iPAH and CTEPH. A positive V/Q 
scan in patients with CTEPH generally shows one or more 
segmental-sized or larger mismatched perfusion defects and 
warrants pulmonary angiography for definitive diagnosis.19,35
Assessment of exercise capacity
Assessment of exercise capacity, using the 6-minute walk 
test (6MWT) or cardiopulmonary exercise testing is an 
important part of the evaluation of PAH. The goals of exercise 
testing include, but are not limited to: determining maximal 
exercise tolerance; identifying functional capacity; obtaining 
prognostic data; uncovering PHT silent at rest; establishing 
a baseline measure of exercise capacity and following the 
response to therapy. Furthermore, the assessment of exercise 
capacity may provide evidence of contributory reasons for 
symptoms (eg, myocardial ischemia).19,35
Doppler echocardiogram
When PAH is suspected Doppler echocardiography should 
be employed to assess pulmonary artery systolic pressure 
(PASP), right ventricular enlargement (RVE), right atrial 
enlargement (RAE) and RV dysfunction.19,35 An adequate 
Doppler signal from the tricuspid regurgitation jet is required 
to estimate PASP and this may be absent in approximately 
25% of patients.36 Furthermore, the parameters for estimating 
PASP and abnormal thresholds for defining PAH have not 
been standardized. Peak velocity of the tricuspid regurgitant 
jet (TRV), a range of tricuspid gradients, and RVSP have 
all been used.20 To exclude PHT due to left-heart disease, 
left ventricular systolic and diastolic function and valve 
morphology and function should also be assessed. Finally, 
echocardiography with contrast should be used to identify or 
rule out PAH due to congenital heart disease (eg, abnormal 
morphology; shunt).
right-heart catheterization
RHC is required to confirm the presence of PAH, establish 
the specific diagnosis including exclusion of pulmonary 
venous hypertension, determine the severity of hemodynamic 
impairment, test the vasoreactivity of the pulmonary circula-
tion, and to guide subsequent therapy.19,35 A response to a 
vasodilator challenge indicates that a patient may be suitable 
for a trial of high dose calcium-channel blockers (CCBs). 
A PCWP  15 mmHg may indicate left heart disease and 
requires careful evaluation as PAH specific therapies may 
be contraindicated.
Screening
High risk conditions and the likelihood of having PAH 
are shown in Table 4. The ACCP Consensus Statement 
recommends that patients with scleroderma should undergo 
periodic Doppler echocardiography as part of a screening 
program because of the relatively high detection rates of 
PAH and disease severity when it develops.19 Other potential 
causes of PAH do not warrant routine screening (eg, previ-
ous use of appetite suppressant, HIV infection, other CTDs) 
because of the low likelihood of discovering PAH. The ques-
tion of when to begin screening in patients with the potential 
for having familial PAH remains open. Patients with more 
than one family member with PAH related to a mutation in 
the BMPBR2 gene might be considered for genetic testing, 
since a negative test would imply that there is no higher than Journal of Multidisciplinary Healthcare 2009:2 72
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normal risk of developing PAH. However, any test should be 
preceded by extensive family and genetic counseling.37
The availability of new therapies that have been shown 
to slow or prevent progression of PAH has caused a growing 
interest among physicians to diagnose PAH at an early stage. 
Since the range of diagnostic tests required is broad, and 
often specialized in itself, multidisciplinary clinics, consist-
ing of a rheumatologist, cardiologist, respiratory physician 
and a specialist nurse together with allied health services 
(eg, sonography, physiotherapy and radiology) appear 
warranted. Given the complex nature of PAH, there can be 
little doubt, that such clinics would facilitate early diagnosis 
and facilitate access to available therapies according to best 
practice guidelines.38
Treatment approaches  
and priorities
The treatment of PAH has witnessed a dramatic change 
in the past decade. Management guidelines for PAH have 
been published by the ESC7 and the ACCP.39–41 Both of 
these guidelines are in the process of being updated with 
new publications due in 2009. Furthermore, the National 
Pulmonary Hypertension Centres of the United Kingdom and 
Ireland recently released an updated consensus statement on 
the management of PAH in clinical practice.33 Treatment is 
often complex and patients benefit from referral to a center 
that specializes in the treatment of this disorder.34 Here we 
will consider ‘conventional’ therapy, defined as that which 
has been used for patients with PAH in the years prior to 
the development of disease-specific, targeted therapy, and 
PAH-specific therapy separately. An evidence-based treat-
ment algorithm is also proposed. The intention is to provide 
a guide to the selective use of each form of therapy.
Conventional treatment
The aim of therapy in patients with PAH is to improve 
survival, disease-related symptoms and quality of life (QoL). 
Conventional treatment options include oxygen therapy 
in cases of hypoxemia, anticoagulants such as warfarin, 
digoxin and diuretics in cases of right-sided heart failure. If, 
during RHC, the pulmonary vasoreactive tests are positive, 
the treatment of choice is high-dose CCBs, as improved 
survival with long-term use has been demonstrated in this 
cohort of patients.42,43 Vasoreactivity is considered to be 
present when the mPAP has decreased by at least 10 mmHg 
to 40 mmHg or less with normal or high cardiac output after 
intervention with pulmonary vasodilators, such as 100% 
oxygen, nitric oxide inhalation or intravenous prostacyclin.35 
However, less than 10% of patients with iPAH respond 
long term to CCB therapy and even less in other associated 
conditions, such as PAH related to CTD: in many cases 
the test is omitted because the response is so infrequent.35 
For well over 90% of patients, PAH specific therapies are 
indicated first line.
Specific treatment
Classes of drugs available for the treatment of PAH include 
prostanoids (epoprostenol and iloprost), endothelin receptor 
antagonists (ERAs, bosentan, sitaxsentan and ambrisentan) and 
a phosphodiesterase-5 (PDE-5) inhibitor (sildenafil). These 
drugs offer improved symptom control, exercise capacity, 
QoL and cardiopulmonary hemodynamics, as well as the 
prospect of extended survival. However, due to the short-term 
nature of the randomized controlled trials (12–16 weeks), only 
epoprostenol has demonstrated a survival benefit compared 
to patients treated with conventional therapy.44 Figure 1 pres-
ents a proposed algorithm for the therapeutic management of 
Table 4 Patients at risk of developing pulmonary arterial hypertension37
Patient characteristics Risk profile
Patients with known genetic mutations predisposing to PAH 20% chance of developing PAH
First degree relatives in a FPAH family 10% chance of developing PAH
Scleroderma spectrum of disease 27% prevalence of PAH (RSVP  40 mmHg)
Portal hypertension in patients considered for liver transplantation 5% prevalence of PAH (mPAP  25 mmHg and Pvr  3.0 U)
Congenital heart disease with systemic to pulmonary shunts Likely approximately 100% in high flow, non-restrictive L-R shunts
Use of flenfluramine appetite suppressants (3 months) Prevalence of 136/million users based on odds ratio of 23 times 
background
Hiv infection Prevalence 0.5/100
Sickle cell disease Prevalence 9.0/100 (TRV  3.0)
Abbreviations: PHT, pulmonary hypertension; PAH, pulmonary arterial hypertension; FPAH, familial pulmonary arterial hypertension; rSvP, right ventricular systolic pressure; 
mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; L-R, left-to right; HIV, human immunodeficiency virus;   TRV, tricuspid regurgitation velocity; RHC, 
right heart catheterization.Journal of Multidisciplinary Healthcare 2009:2 73
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patients with PAH.45 This algorithm is based on evidence from 
clinical trials performed to date and is focused on patients in 
NYHA functional class II to IV. Furthermore, the algorithm 
is based on therapies that have been evaluated in iPAH, and 
in PAH associated with scleroderma or due to anorexigens. 
Extrapolation of trial results to other PAH subgroups should 
be done with caution.
For patients classified as NYHA class II, III or IV, there 
are a number of therapeutic options. Bosentan is an oral dual 
endothelin-A (ETA) and endothelin-B (ETB)-receptor antagonist. 
It is the first molecule of this class of drugs to be synthesized. 
Activation of ETA and ETB-receptors on smooth muscle cells 
mediate the vasoconstrictive and mitogenic effects of ET-1, 
and the prominent role of ET-1 in the pathogenesis of PAH 
has been well documented.46,47 The efficacy of bosentan has 
been extensively studied in five randomized placebo-controlled 
trials48–52 and five open-label studies.53–57 In these trials, bosentan 
demonstrated improvements in exercise capacity, functional 
class, hemodynamics, echocardiographic and Doppler variables, 
and time to clinical worsening. Additional ERAs have since 
been developed (eg, sitaxsentan and ambrisentan) that target 
the ETA receptor only, with similar efficacy results. Slightly less 
long-term evidence is available for these agents.58–61
The prostacyclin analogue, epoprostenol has been 
approved for the treatment of patients with iPAH in NYHA 
class III and IV. In several randomized controlled trials, 
the beneficial effects of epoprostenol were demonstrated 
on survival, exercise tolerance, functional class and pulmo-
nary vascular hemodynamics.44,62–64 Despite its benefits, the 
complexity of drug administration limit its use. Epoprostenol 
is recommended first line for those patients presenting with 
functional class IV symptoms. Several additional prostacylin 
analogues, namely iloprost, treprostinil and beraprost, have 
also been developed with less utility than epoprostenol.
More recently, sildenafil, an oral PDE-5 inhibitor, has 
been shown to be effective in patients with iPAH.65 PDE-5 
exerts its pharmacological effect by increasing the intracel-
lular concentration of cGMP. The increase of this nucleotide 
induces relaxation and antiproliferative effects on vascular 
smooth muscle cells.7
For patients in functional class II–III, therapeutic efficacy of 
the PAH-specific agents is evaluated after 3 months and every 3 to 
PAH
NYHA FUNCTIONAL CLASS II/III/IV
Sustained response to
Ca Channel Blocker?
Refractory to treatment
Maintain therapy
Atrial septostomy +/− Lung transplant
AND/OR
COMBINATION PHARMACOTHERAPY
(IV epoprostenol/inh.IIoprost/treprostinil)/
(epoprostenol/IIoprost/treprostinil)
(bosentain/sitaxsentan/ambrisentan)
Endothelin Receptor Antagonist
(bosentan)
YES
NO
NO
YES
NYHA Class IV
NYHA Class II or III
Prostanoid Analogue
Endothelin Receptor Antagonist
Prostanoid Analogue
PDE - 5 Inhibitor
(sildenafil)
Oxygen support +/−  diuretic therapy
CONVENTIONAL THERAPY
VASOREACTIVE
?
Figure 1 Proposed algorithm for the medical management of pulmonary arterial hypertension (PAH).41   A positive acute response to vasodilators is defined as a fall in mPAP 
of at least 10 mmHg to 40 mmHg, with an increased or unchanged cardiac output during acute challenge with inhaled nitric oxide, iv epoprostenol, or iv adenosine. Sustained 
response to calcium channel blockers is defined as patients being in functional class I or II with near-normal hemodynamics after several months of treatment. Most experts 
recommend that patients in functional class IV in unstable condition be treated with iv epoprostenol. In patients in functional class III, first-line therapy may include oral 
endothelin-receptor antagonists, phosphodiesterase inhibitors, long-term iv epoprostenol, or prostanoid analogues.
Abbreviation: PDe, phosphodiesterase.Journal of Multidisciplinary Healthcare 2009:2 74
Strange et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
6 months thereafter and more frequently in functional class IV. 
If treatment with initial therapy fails, the next treatment option, 
usually an agent with a different mode of action is administered, 
or continuous intravenous epoprostenol considered.
Combination therapy
The optimal management of patients who exhibit clinical 
deterioration despite targeted monotherapy remains a matter of 
debate.33 Follow-up beyond the first 3 months of therapy with 
oral, inhaled or intravenous agents shows that a proportion of 
patients deteriorate. For example, the percentage of patients 
remaining stable on bosentan monotherapy at 1 year is 85%,66 
and 57% at 3 years.67 Similarly, for sildenafil monotherapy, 
85% of patients are stable at 1 year,65 as are 85% on epopro-
stenol64 and 42% to 77% on inhaled iloprost.68,69 With the 
development of several therapeutic agents with different mech-
anisms of action and potential synergy, considerable interest 
has developed in the possibility of combination therapy.
At the time of writing, concomitant combination therapy 
has not been adequately studied. The single small trial of 
epoprostenol initiation with add on bosentan 48 hours later 
showed only trends in improvement, without significant 
benefits.37 In contrast, sequential add on therapy has achieved 
successful endpoints for a wide range of combinations 
(eg, bosentan add iloprost, epoprostenol add sildenafil, bosentan 
add sildenafil, beraprost or iloprost add bosentan, treprostinil 
add bosentan, and iloprost add sildenafil).37 For example, in the 
PACES-1 trial, Simonneau et al randomized 267 patients with 
Class III or IV disease (iPAH, CTD-related PAH or CHD-PAH) 
receiving epoprostenol continuous iv infusion, to either 
added sildenafil or placebo.70 At 16 weeks, sequential therapy 
significantly improved 6MWD compared to monotherapy 
(+26 m; p  0.001), decreased mPAP (p  0.001), and 
increased time to clinical worsening (p = 0.012).
Combination therapy remains an attractive option, and 
individuals who demonstrate an inadequate response to 
monotherapy should be considered for a combination of 
two or more disease-targeted therapies. However, given the 
limited amount of conclusive data pertaining to combination 
treatment, published guidelines have so far made no specific 
recommendation to guide clinicians on the next step to 
improve the status of their patients who continue to decline 
on monotherapy.33
Transplant
A small proportion of patients with PAH are eligible for 
heart-lung or bilateral lung transplantation. This treatment 
option should be considered and early discussion with 
experienced transplant physicians is recommended. However, 
limited donors supply and a 5-year survival of approximately 
50%, significantly restricts its utlility.71 Consideration should 
be given to referring patients to centers that are experienced 
in atrial septostomy where available.72
Patient management issues  
and non-drug interventions
PAH is a chronic, life-shortening disease and many patients 
suffer from limitations in their physical mobility, energy, 
emotional reactions and social isolation. It is therefore 
essential that the multidisciplinary team involved with the 
care of patients with PAH is highly skilled in managing 
the burden and impact of the disease, and its complex and 
often intrusive therapies at both physical and psychological 
levels. Understandably, many PAH patients are affected 
by a degree of anxiety and/or depression that can have a 
profound impact on their QoL. Assisting patients to adapt 
to the uncertainty associated with their illness is important, 
as is referral to psychologists or psychiatrists when needed. 
Support groups for patients, families and carers are useful 
in improving the understanding and the acceptance of the 
disease condition.
QoL has been shown to be low in patients with PAH 
using the 36-Item Short-Form Health Survey (SF-36),73 the 
Nottingham Health Profile (NHP), the Congestive Heart 
Failure Questionnaire (CHQ) and the Hospital Anxiety and 
Depression Scale (HADS).1 Improvements in QoL have been 
reported in trials of PAH-specific therapy and improvements 
over pre-treatment scores have been seen in association with 
increased exercise capacity.44,74–79 However, exercise capacity 
and QoL in patients with PAH are not necessarily related. 
One study found an absence of any significant relationship in 
changes in 6MWT distance and changes in QoL in response 
to therapy,80 concluding that these measures provide comple-
mentary data in terms of response to therapy. A new disease 
specific patient report outcome instrument, CAMPHOR has 
recently been developed and correlates well with current 
surrogate outcomes. An assessment such as CAMPHOR 
should be used in routine clinical practice to assess the QoL 
status of patients with PAH.33
PAH is a contraindication to pregnancy. Patients with 
PAH require counseling regarding the very high risk of 
pregnancy-related mortality (approx. 30%) and the need for 
adequate contraception. Although the WHO advises dis-
cussing termination in the event of pregnancy, if a patient is 
fully informed and understands the risks of proceeding with 
pregnancy, treatment with some PAH-specific therapies may Journal of Multidisciplinary Healthcare 2009:2 75
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represent a realistic option and may improve the chances of 
maternal survival.33
Finally, patients should be also be encouraged to be as 
active as their symptoms allow.33 A recent study has demon-
strated an improvement in exercise capacity in patients who 
took part in a training program.81
Optimal structure and organization 
of multidisciplinary care
Effective diagnosis and treatment of PAH, where several 
clinical pathways and scenarios are possible, relies on the 
expertise of many clinical specialties with the knowledge 
and skill to meet the holistic needs of the patient and their 
carers.33 These needs include information about the disease 
and its prognosis, education and support in managing com-
plex drug therapies, psychological and social support, and 
access to local support in the community. It stands to reason 
that this care is best achieved when these specialists work 
together in multidisciplinary teams.
Multidisciplinary care involves a team approach to the 
provision of care by multiple medical and allied health 
disciplines. The liaison and cooperation of team members 
together with the patient ensures that all relevant treatment 
methods that have a place in the modern management of 
PAH are properly considered – from diagnosis through 
follow-up. The effectiveness of multidisciplinary care and 
coordinated specialty units has been well documented in other 
conditions, namely heart failure,82 stroke83,84 and oncology.85 
To date, however, there is no comprehensive information 
describing how, or to what extent, institutions managing 
PAH in Australia have adopted a multidisciplinary approach. 
In Western Australia, the state referral center for PAH is 
located at the Royal Perth Hospital. The composition and 
roles of the multidisciplinary team are shown in Table 5. 
We conducted independent observations and interviews 
with members of the team to elicit further information 
about the organization, style, leadership and benefits of the 
multidisciplinary approach.
At this center, patients suspected of having PAH are first 
seen by a specialist nurse coordinator. The mode of referral is 
variable. Some patients may be identified by hospital physi-
cians or family doctors as outpatients. Others are referred 
from related initiatives such as the scleroderma screening pro-
gram.38 The nurse coordinator is responsible for organizing 
initial screening examinations including echocardiography, 
ECG and CXR. Once this information is collated, the patient 
is seen by a respiratory physician. When required, additional 
assessments are organized by the nurse coordinator, and may 
include consultation with a cardiologist. If the results of the 
examinations are indicative of PAH, RHC is carried out. 
After the results of all tests have become available, patients 
are discussed by the multidisciplinary team, appropriate 
treatment is discussed and a management plan developed. 
The management plan is then proposed to the patient during a 
follow up visit. All consenting patients with confirmed PAH 
are entered into a PAH registry.
Table 5 Composition and roles of the royal Perth Hospital PAH multidisciplinary team
Discipline Role
Team coordinator Organization of resources, administration meetings and educational sessions
respiratory medicine Diagnostic evaluation; medical treatment; patient and family education; staff and trainee education; research; program 
evaluation
Cardiology Diagnostic evaluation; medical treatment; patient and family education; staff and trainee education; research; program 
evaluation
rheumatology Diagnostic evaluation; medical treatment; patient and family education; staff and trainee education; research; program 
evaluation
Nursing Assessment and provision of care needs; support and education for patients and families
Clinical trials Data entry, registry management and protocol execution of clinical trials; research accounting and administration
Physiotherapy Assessment of exercise capacity. Guidance related to exercise programmes for appropriate patients
Social work emotional adjustment and counseling for patients and families; assessment of resources required; referral to appropriate 
community agencies; patient and family planning
Dietetics Assessment of nutritional status and requirements; implementation of appropriate diet plan; patient and family education
Pharmacy Consultation for matters relating to drug therapy; patient and family education
rehabilitation Assessment of impairment and disability; patient and family education
radiology Diagnostic evaluation; echocardiography
Transplantation Patient evaluation, surgical and medical treatment; patient and family educationJournal of Multidisciplinary Healthcare 2009:2 76
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Analysis of the observations and interviews with par-
ticipants about their perceptions of the multidisciplinary 
structure revealed several common elements related to the 
success of a unit. These include, but are not limited to:
•  A team approach, involving core disciplines integral 
to the provision of PAH management, with input from 
other specialties as required (where ‘core’ disciplines are 
cardiology, rheumatology, respiratory, radiology, and 
supportive care).
•  Communication among team members regarding treat-
ment planning via regular multidisciplinary meetings held 
at regular times, venues and with consistent formats to 
the delivery of information.
•  Equivalent access to care for all patients, regardless of 
geographical location.
•  Provision of care in accord with international guide-
lines.
Strong leadership was also raised by several members as 
a key element to the success of the multidisciplinary team: 
coordinating and chairing regular meetings, encouraging 
involvement of all participants in case discussions and 
decision-making and, at the conclusion of case discussions, 
summarizing the discussion and inviting any further input 
before moving to the next case. Motivational factors for 
attending meetings included, 1) perceived benefits of the 
meetings for both meeting participants and patients, 2) an 
opportunity to interact with other members of the multidis-
ciplinary team in an inclusive atmosphere, 3) an opportunity 
for educational interaction and professional development, 
and 4) streamlining of referral pathways. Meetings may 
also serve as a resource of identifying patients suitable 
for clinical trial participation. An established center for 
managing disease also allows for the collection of registry 
data on patient presentations, patterns of care and treatment 
outcomes. This provides a comprehensive set of information 
available to guide future management, clinical research and 
treatment practices.
Clearly, the way in which multidisciplinary care is 
best structured and implemented will vary between sites 
and depend on local, political and financial resources. For 
example, geographical remoteness may require collabora-
tions to use telemedicine for multidisciplinary case con-
ferencing. In other situations, the appointment of a nurse 
coordinator as a focal point for patients being treated by 
several facilities within a collaborative may represent an 
avenue of streamlining patient care and ensuring that patients 
are managed according to agreed guidelines and receive 
adequate follow-up. However, regardless of the structure in 
place, the diverse nature and complexity of PAH is an area 
of medicine in need of multidisciplinary care. The next step, 
and an avenue for future research, will be to evaluate whether 
care provided by a multidisciplinary team can improve long-
term outcomes in patients with PAH, as has been the case in 
patients suffering from heart failure82 and stroke.83,84
Conclusion
The treatment of PAH has realized dramatic advances over 
the past decade, and it is clear that the PAH-specific thera-
pies can significantly alter the natural history of the disease. 
Despite this, there remains a need to identify patients with 
PAH earlier, before the onset of extensive vascular remodel-
ing. This can be achieved by performing a thorough assess-
ment to rule out other diagnostic possibilities and to establish 
the type of PAH. Once identified, it is essential that patients 
are provided with adequate care and follow-up in line with 
evidence-based guidelines. Effective diagnosis and treatment 
of PAH is complex and challenging, relying on the expertise 
of a team of specialists including rheumatologists, respira-
tory physicians, cardiologists and specialized nurses. The 
collaboration of a well coordinated multidisciplinary team of 
healthcare professionals accounts for the most optimal diag-
nostic and therapeutic procedures and ensures that patients 
receive the best possible care.
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